Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dicker

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Cancer Biology & Therapy|November 20, 2009
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyesJoshua E Allen, Lori S Hart, David T Dicker, et al.
Cell Cycle (Georgetown, Tex.)|July 28, 2017
CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXALiz J Hernandez-Borrero, Shengliang Zhang, Amriti Lulla, et al.
Cancer Biology & Therapy|August 15, 2002
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 proteinRishu Takimoto, Wenge Wang, David T Dicker, et al.
Cancer Biology & Therapy|August 13, 2002
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiationRishu Takimoto, Timothy K MacLachlan, David T Dicker, et al.
Cancer Biology & Therapy|December 30, 2009
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-RasArunasalam Navaraj, Niklas Finnberg, David T Dicker, et al.
American Journal of Cancer Research|February 10, 2022
miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cellsAmriti R Lulla, Yan Zhou, Marie D Ralff, et al.
Scientific Reports|October 23, 2021
Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90Shuai Zhao, Lanlan Zhou, David T Dicker, et al.
Cancer Biology & Therapy|July 16, 2011
Spectral imaging-based methods for quantifying autophagy and apoptosisNathan G Dolloff, Xiahong Ma, David T Dicker, et al.
Cancer Biology & Therapy|September 9, 2017
Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancerAvital Lev, Safoora Deihimi, Elena Shagisultanova, et al.
Science Translational Medicine|June 10, 2011
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulationNathan G Dolloff, Patrick A Mayes, Lori S Hart, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Cancer Biology & Therapy|November 20, 2009
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyesJoshua E Allen, Lori S Hart, David T Dicker, et al.
Cell Cycle (Georgetown, Tex.)|July 28, 2017
CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXALiz J Hernandez-Borrero, Shengliang Zhang, Amriti Lulla, et al.
Cancer Biology & Therapy|August 15, 2002
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 proteinRishu Takimoto, Wenge Wang, David T Dicker, et al.
Cancer Biology & Therapy|August 13, 2002
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiationRishu Takimoto, Timothy K MacLachlan, David T Dicker, et al.
Cancer Biology & Therapy|December 30, 2009
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-RasArunasalam Navaraj, Niklas Finnberg, David T Dicker, et al.
American Journal of Cancer Research|February 10, 2022
miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cellsAmriti R Lulla, Yan Zhou, Marie D Ralff, et al.
Scientific Reports|October 23, 2021
Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90Shuai Zhao, Lanlan Zhou, David T Dicker, et al.
Cancer Biology & Therapy|July 16, 2011
Spectral imaging-based methods for quantifying autophagy and apoptosisNathan G Dolloff, Xiahong Ma, David T Dicker, et al.
Cancer Biology & Therapy|September 9, 2017
Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancerAvital Lev, Safoora Deihimi, Elena Shagisultanova, et al.
Science Translational Medicine|June 10, 2011
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulationNathan G Dolloff, Patrick A Mayes, Lori S Hart, et al.
Pageof 10